Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Gives OTCs “Major” Role In 2014 Outlook

This article was originally published in The Tan Sheet

Executive Summary

The Israeli firm reassures investors that the business is stable and is moving forward with strategic plans after the abrupt exit of its CEO. Teva’s OTC business will be a key driver of those plans, says interim CEO Eyal Desheh.

You may also be interested in...

PGT Healthcare Aims To Unlock Value Of Existing Portfolios

PGT Healthcare CEO Briain de Buitleir and COO Eli Shani say the joint venture will help Teva realize greater value for its localized OTCs and enable Procter & Gamble to expand its nutritional products portfolio.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Zafgen Drops Beloranib, But Its New Focus Raises Doubts

The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts